HI
SPRY icon

Harbour Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Harbour Investments’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Buy
+1,870
New +$17.9K ﹤0.01% 3049

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Harbour Investments's SPRY Position: Q1 2026 in Review

Harbour Investments opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 1,870 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #3049 among its holdings.

202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Harbour Investments held 1,870 shares of ARS Pharmaceuticals worth $15K as of Q1 2026.
  • ARS Pharmaceuticals was a new Harbour Investments position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #3049 holding.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.